Drug Profile
GSK 704838
Alternative Names: GSK704838Latest Information Update: 01 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antiasthmatics
- Mechanism of Action Cholinergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 18 Feb 2014 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
- 29 Feb 2008 GlaxoSmithKline completes a phase I trial in Healthy volunteers in United Kingdom (NCT00539825)
- 30 Sep 2007 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)